Skip to main content

Table 1 Baseline characteristics

From: Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population

Parameter LX TBP P value
(N = 255) (N = 299)
Age (year)
  < 50 137(53.7%) 161(53.8%) 0.977
  ≥ 50 59(23.1%) 95(31.8%) 0.024
 Unknown 59(23.1%) 43(14.4%) 0.008
Menopausal status
 Premenopausal 40(15.7%) 68(20.7%) 0.126
 Postmenopausal 182(71.4%) 204(68.2%) 0.422
 Unknown 33(12.9%) 27(9%) 0.14
HR Status
 Negative 136(53.3%) 145(48.5%) 0.256
 Positive 92(36.1%) 139(46.5%) 0.013
 Unknown 27(10.6%) 15(5%) 0.014
 Stage IV at initial diagnosis 32(12.5%) 55(18.4%) 0.059
Number of metastatic sites
  < 3 178(69.8%) 190(63.5%) 0.12
  ≥ 3 77(30.2%) 109(36.5%)  
Metastases
 Lung 123(48.2%) 162(54.2%) 0.163
 Liver 109(42.7%) 143(47.8%) 0.213
 Bone 62(24.3%) 86(28.8%) 0.238
 Brain 24(9.4%) 34(11.4%) 0.453
 Other 131(51.4%) 150(50.2%) 0.78
Resistance
 Primary 96(37.6%) 109(38.1%) 0.772
 Secondary 159(62.4%) 190(61.9%)  
Treatment line
 1 37(14.5%) 43(14.4%) 0.966
 2 94(36.9%) 164(54.8%) <0.001
 3 124(48.6%) 92(30.8%) 0.001
Previous therapy
 Hormonal
  Adjuvant 76(29.8%) 96(32.1%) 0.559
  Metastatic 60(23.5%) 91(30.4%) 0.069
Radiotherapy
 Adjuvant 86(33.7%) 104(34.8%) 0.794
 Metastatic 44(17.3%) 54(18.1%) 0.804
Previous trastuzumab failure
 Adjuvant 37(14.5%) 43(14.4%) 0.966
 Metastatic 218(85.5%) 256(85.6%)  
Previous trastuzumab treatment
 Adjuvant 78(30.6%) 67(22.4%) 0.029
 Advanced disease only 177(69.4%) 232(77.6%)